Marina Biotech, Tekmira Enter Worldwide Non-Exclusive Licensing Agreement for Nucleic Acid Chemisty
Marina Biotech, Inc. announced today that it has entered into a license agreement with Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), where Marina will provide Tekmira a worldwide, non-exclusive license to Marina Biotech's Unlocked Nucleobase Analog (UNA) technology for the development of RNA interference therapeutics. Tekmira will have full responsibility for the development and commercialization of any products arising under the Agreement. Under terms of the Agreement, Marina Biotech will receive an upfront payment plus milestone and royalty payments on products developed by Tekmira that use UNA technology. Further terms of the Agreement were not disclosed.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.